Group 1 - The innovative drug sector has been experiencing a continuous adjustment since September, with the Hong Kong stock index related to innovative drugs declining by over 20% [1] - Some unprofitable companies in the sector have seen their stock prices drop by more than 40%, indicating a significant market reaction [1] - Investor sentiment has shifted as previously abundant capital begins to exit the market, reflecting a heightened emotional threshold among investors [1] Group 2 - The number of IPOs and the amount of financing for innovative drug companies in Hong Kong have significantly increased this year, leading to controversy among market participants [1] - Industry insiders believe that while the long-term beta logic of the innovative drug sector remains unchanged, the focus on pricing needs to return to the companies themselves [1]
创新药投资已至岔路口，基金经理热议融资潮
Xin Lang Cai Jing·2025-12-28 23:34